A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Bladder cancer; Cholangiocarcinoma; Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 20 Apr 2017 Results published in a RedHill Biopharma media release.
    • 20 Apr 2017 According to a RedHill Biopharma media release, data from this study has been published in Clinical Cancer Research.
    • 18 Apr 2017 Results assessing safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of ABC294640, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top